Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration

Nancy Vander Velde,Annie Guerin,Raluca Ionescu-Ittu,Sherry Shi,Eric Q. Wu,Shih-Wen Lin,Ling-I Hsu,Kai-Uwe Saum,Sabine de Ducla,Jingjing Wang,Shi Li,AnnChristine Thåström,Shuqian Liu,Lizheng Shi, John T. Leppert

European Urology Oncology（2019）

引用 18|浏览11

暂无评分

摘要

Comparative effectiveness analyses of non-cisplatin first-line treatment for metastatic urothelial carcinoma with atezolizumab (from the phase 2 IMvigor210 trial cohort) versus carboplatin-based chemotherapy regimens (from US Veterans Health Administration cohorts) suggested an overall survival benefit with atezolizumab that was apparent several months after treatment initiation.

查看译文

关键词

Atezolizumab,Chemotherapy,Comparative effectiveness,Entropy balancing,First-line treatment,Immunotherapy,Metastatic urothelial carcinoma,Real-world data

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要